[go: up one dir, main page]

WO2000030669A3 - Utilisation de proteines de transfert des phospholipides plasmatiques pour le traitement de maladies cardio-vasculaires - Google Patents

Utilisation de proteines de transfert des phospholipides plasmatiques pour le traitement de maladies cardio-vasculaires Download PDF

Info

Publication number
WO2000030669A3
WO2000030669A3 PCT/NL1999/000720 NL9900720W WO0030669A3 WO 2000030669 A3 WO2000030669 A3 WO 2000030669A3 NL 9900720 W NL9900720 W NL 9900720W WO 0030669 A3 WO0030669 A3 WO 0030669A3
Authority
WO
WIPO (PCT)
Prior art keywords
dieases
phospholipid transfer
treating cardiovascular
plasma phospholipid
transfer proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL1999/000720
Other languages
English (en)
Other versions
WO2000030669A2 (fr
Inventor
Crom Marinus Petrus Gerardu De
Gent Teunis Van
Haperen Marinus Johannes Van
Tol Arie Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus Universiteit Rotterdam
Original Assignee
Erasmus Universiteit Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus Universiteit Rotterdam filed Critical Erasmus Universiteit Rotterdam
Priority to AU14168/00A priority Critical patent/AU1416800A/en
Publication of WO2000030669A2 publication Critical patent/WO2000030669A2/fr
Publication of WO2000030669A3 publication Critical patent/WO2000030669A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne le domaine des maladies cardio-vasculaires, en particulier celui des maladies associées à des concentrations plasmatiques élevées du cholestérol et/ou des triglycérides chez les mammifères, en particulier chez l'homme. Selon l'invention, la protéine de transfert des phospholipides plasmatiques (PLTP) présente des effets pharmaceutiques bénéfiques et il est possible de produire, sur la base de la PLTP, des compositions pharmaceutiques pour le traitement d'affections cardio-vasculaires.
PCT/NL1999/000720 1998-11-24 1999-11-23 Utilisation de proteines de transfert des phospholipides plasmatiques pour le traitement de maladies cardio-vasculaires Ceased WO2000030669A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14168/00A AU1416800A (en) 1998-11-24 1999-11-23 Use of plasma phospholipid transfer proteins in treating cardiovascular dieases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203962 1998-11-24
EP98203962.0 1998-11-24

Publications (2)

Publication Number Publication Date
WO2000030669A2 WO2000030669A2 (fr) 2000-06-02
WO2000030669A3 true WO2000030669A3 (fr) 2000-10-19

Family

ID=8234379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1999/000720 Ceased WO2000030669A2 (fr) 1998-11-24 1999-11-23 Utilisation de proteines de transfert des phospholipides plasmatiques pour le traitement de maladies cardio-vasculaires

Country Status (2)

Country Link
AU (1) AU1416800A (fr)
WO (1) WO2000030669A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018227A1 (fr) * 1993-12-30 1995-07-06 Zymogenetics, Inc. Proteines de transfert de phospholipides
WO1995034289A1 (fr) * 1994-06-14 1995-12-21 The Rockefeller University Compositions pour la neutralisation de lipopolysaccharides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018227A1 (fr) * 1993-12-30 1995-07-06 Zymogenetics, Inc. Proteines de transfert de phospholipides
WO1995034289A1 (fr) * 1994-06-14 1995-12-21 The Rockefeller University Compositions pour la neutralisation de lipopolysaccharides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. FÖGER ET AL.: "PLASMA PHOSPHOLIPID TRANSFER PROTEIN.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 43, 24 October 1997 (1997-10-24), MD US, pages 27393 - 27400, XP002109523 *
J.J. ALBERS ET AL.: "TRANSGENIC MICE EXPRESSING HUMAN PHOSPHOLIPID TRANSFER PROTEIN HAVE INCREASED HDL/non-HDL CHOLESTEROL RATIO.", INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, vol. 26, no. 4, December 1996 (1996-12-01), HEIDELBERG, DE, pages 262 - 267, XP002109521 *
R. VAN HAPEREN ET AL.: "HUMAN PLASMA PHOSPHOLIPID TRANSFER PROTEIN INCREASES THE ANTIATHEROGENIC POTENTIAL OF HIGH DENSITY LIPOPROTEINS IN TRANSGENIC MICE.", ARTHERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 20, no. 4, April 2000 (2000-04-01), DALLAS, TX, US, pages 1082 - 1088, XP000915014 *
X.-C. JIANG ET AL.: "INCREASED PRE-BETA-HIGH DENSITY LIPOPROTEIN, APOLIPOPROTEIN AI, AND PHOSPHOLIPID IN MICE EXPRESSING THE HUMAN PHOSPHOLIPID TRANSFER PROTEIN AND HUMAN APOLIPOPROTEIN AI TRANSGENES.", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 98, no. 10, 15 November 1996 (1996-11-15), NEW YORK, N.Y., US, pages 2373 - 2380, XP002109522 *

Also Published As

Publication number Publication date
AU1416800A (en) 2000-06-13
WO2000030669A2 (fr) 2000-06-02

Similar Documents

Publication Publication Date Title
WO1998033509A3 (fr) Proprietes utiles de la lactoferrine humaine et de variants de celle-ci
WO2004019884A3 (fr) Agents et procedes pour stimuler la formation osseuse
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
WO2003009704A3 (fr) Compositions enterale permettant de prevenir et/ou de traiter une sepsie
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
ZA947529B (en) Inhibitors of beta-amyloid protein production
ZA966798B (en) Methods of reducing or maintaining reduced levels of blood lipids using OB protein compositions.
NO20063328L (no) Anvendelse av en fettsyresammensetning som innbefatter minst en av EPA og DHA eller kombinasjoner derav
HK1044543B (zh) 贝他分泌酶组合物及其方法
AU4835693A (en) Pharmaceutical composition comprising phosphatase or a derivative thereof
EP0797999A3 (fr) Formulations de protéine d'obésité
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
ATE355057T1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
WO2007002836A3 (fr) Procedes et compositions pour la prevention et le traitement de maladie renale
WO1996013498A3 (fr) Nucleosides l-erythrosyle
WO2000030669A3 (fr) Utilisation de proteines de transfert des phospholipides plasmatiques pour le traitement de maladies cardio-vasculaires
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
WO2003092701A3 (fr) Utilisation d'acides amino-alcane-phosphoniques substitués
PT782630E (pt) Gene da doenca poliquistica do rim
WO1999058098A3 (fr) Antithrombines iii humaines et procedes connexes
WO1999055859A3 (fr) Proteines a interaction cd40 et a interaction traf
WO2002083700A3 (fr) Disaccharides hypersulfates et leur utilisation en traitement contre les inflammations
AU2010792A (en) Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
NO951762D0 (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 14168

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase